New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2025
0mins
Source: Globenewswire
Research Findings: LIXTE Biotechnology has published new pre-clinical data showing that LB-100, a cancer treatment compound, is converted into its active form endothall by an enzyme, which may serve as a biomarker to identify patients likely to respond to the treatment.
Clinical Implications: The findings enhance understanding of LB-100's biological availability and aim to optimize patient selection for ongoing clinical trials targeting ovarian and colorectal cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
